Identifying bryostatins and potential precursors from the bryozoan Bugula neritina
- 1 July 2005
- journal article
- research article
- Published by Taylor & Francis in Natural Product Research
- Vol. 19 (5) , 467-491
Abstract
The bryozoan species Bugula neritina contains the anticancer agent bryostatin. Bryostatin has been extracted from these sessile marine invertebrates since the late 1960s from the Gulf of California, Gulf of Mexico, as well as various locations on the eastern and western rims of the Pacific Ocean. In this work we are focusing on animals harvested in the Gulf of Mexico near Alligator Point (Florida). Using Inductively Coupled Plasma-Mass Spectrometry (ICP–MS) we measure the concentration of 70 elements in B. neritina, a sea squirt, and the sediment from the point of harvesting. This data has helped us generate an extraction process for marine natural products. Combining UV/VIS absorbance measurements with Matrix Assisted Laser Desorption Ionization–Time of Flight-Mass Spectrometer (MALDI–TOF-MS), we demonstrated that the specific form of bryostatin extracted is a function of the solvent. A 9.4 T Fourier Transform-Ion Cyclotron Resonance (FT-ICR) mass spectrometer, whose sensitivity, mass accuracy, and resolving power allowed the exact empirical formulas of potential precursors of bryostatin to be identified, was employed. Finally we examine extracts of 14 marine species of the Gulf of Mexico, from the sand trout (Cynoscion arenarius) to chicken liver sponge (Chrondrilla nucula), all recently collected, which had shown some medicinal activity thirty years ago in a National Cancer Institute study. By the MALDI–TOF-MS, we were able to identify mass spectral features that correspond to different variations of the basic bryostatin structure, which raises the question if the bryozoans are the original source of bryostatin.Keywords
This publication has 29 references indexed in Scilit:
- Natural Products as Sources of New Drugs over the Period 1981−2002Journal of Natural Products, 2003
- Inspirations from nature. New reactions, new therapeutic leads, and new drug delivery systemsPure and Applied Chemistry, 2003
- The clinical development of the bryostatinsAnti-Cancer Drugs, 2002
- Chemistry and clinical biology of the bryostatinsBioorganic & Medicinal Chemistry, 2000
- The rational design of potential chemotherapeutic agents: Synthesis of bryostatin analoguesMedicinal Research Reviews, 1999
- Total Synthesis of Bryostatin 2Journal of the American Chemical Society, 1999
- Bryostatin 1: Differentiating agent from the depthsLeukemia Research, 1997
- Antineoplastic agents. 224. Isolation and structure of neristatin 1Journal of the American Chemical Society, 1991
- Antineoplastic agents 100Tetrahedron, 1985
- Structure of bryostatin. 4. An important antineoplastic constituent of geographically diverse Bugula neritina (Bryozoa)Journal of the American Chemical Society, 1984